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laucoma is leading towards the second most common cause of worldwide irreversible blindness 1 and approximately sixty million people are suffering from glaucoma globally 1, 2 . Glaucoma therapies are designed to either increase the outflow or decrease the production of aqueous humor in order to reduce intraocular pressure (IOP) and preserve visual function 3 . Studies have shown that reducing intraocular pressure helps to preserve visual function in most cases 3 . Surgical intervention is needed when medication fails to control intraocular pressure (IOP), which is required to preserve optic nerve function 4 . Current glaucoma therapies include topical medications, laser therapies, microinvasive glaucoma surgery, and incisional glaucoma surgery. Most therapies are designed to reduce the production of aqueous humor, increase uveoscleral outflow or both 5 .
Trabeculectomy with or without anti-metabolites, and glaucoma drainage devices are considered to be the initial IOP lowering surgical procedures followed by 6 Cycloablation, in which destruction of ciliary body epithelium and stroma is done, thus reducing aqueous production 7 . Cyclo G6 system with MP3 probe, deliver microsecond thermal energy that is confined to target tissue, preventing destruction of surrounding tissue by on and off cycles mode, allowing energy to build up in the targeted pigmented tissues, reaching to coagulative threshold 7 .
In Ten et al study the mean preoperative IOP was 39. 3 [9] [10] [11] [12] [13] [14] . Reduction of mean IOP was seen in 60.3% at 1 week and 33.4% at 1 month. The procedure was safe in all cases and effectiveness was found in 71% of the patients 15 .
There are few international studies in literature describing the clinical outcomes of micropulsed mp3 cyclodiode laser, in which the work is mostly done in patients with advanced glaucoma with no local studies. The aim of this study is to consider MP3 cyclodiode laser for other glaucoma patients, to control intraocular pressure with the reduction of number of treatments especially excluding the oral acetazolamide to minimize collateral damage, unwanted side effects and to overcome the unavailability of this drug in Pakistan. Clinical history was recorded. Informed written consent was taken before enrolment. Data was collected using a proforma, which included age, gender, duration of glaucoma, number of antiglaucoma medications, visual acuity using Snellen chart and intraocular pressure with the Goldmann Applanation tonometer. Type of glaucoma was labeled after slit lamp examination. The Micro pulse trans-scleral cyclophotocoagulation (MPTSCPC) diode laser procedure was performed after injecting retro bulbar anesthesia of 3-5ml of lidocaine. Cyclo G6 laser system (IRIDEX laser system) which uses a laser diode of 810 nm infrared wavelength with MP3 probe was used. Treatment was done using total duration of 1.6 millisecond (ms) including 0.5 millisecond on time, 1.1 ms off time, 31.33% duty cycle and power of 2000 mW. Globe manipulation by cotton swabs and placement of speculum was censured by adequate exposure to the targeted area. The laser probe was positioned perpendicular to the surface of the globe with fiberoptic tip 3 mm away from the limbus. Laser application was done to the upper and lower hemisphere in "painting" direction, avoiding the 3 and 9 o'clock positions to avoid risk of damage to the neurovascular bundles. The laser was delivered for 80 seconds for superior and inferior hemisphere for a total of 160 seconds of treatment. Patients received post-operative dose of dexamethasone ointment and were patched for 1 hour. All patients were started on topical Moxifloxicin, Fluoromethalone and neomycin one hourly and after 1 week tapered to 4 times a day. The following baseline parameters were collected for each visit at 1 week, 1 month and 3 months. Intraocular pressure, number of anti-glaucoma medications used including oral acetazolamide and any complications were recorded. Topical antiglaucoma medications were tapered or adjusted at the doctor's discretion. Effectiveness of the procedure of the treated eyes was defined as reduction of IOP by 30% from baseline IOP after 1 month follow up or withdrawal of oral acetazolamide. SPSS version 22 was used for data compilation and analysis. Frequencies and percentages were computed for categorical variables. Quantitative variables were presented as mean ± standard deviation. The mean baseline IOP was compared with mean IOP at 3 months using student t test. Effect modifiers were controlled through stratification. Poststratification chi square and fisher exact test was used to see the association of effectiveness with stratified groups. Repeated measures of ANOVA were applied Pak J Ophthalmol to compare means. P value ≤0.05 was considered level of significance.
MATERIAL AND METHODS

RESULTS
Ninety-eight cases were included in study. Out of whom 62 (63.3%) were males and 36 (36.7%) were females. The descriptive statistics including mean age of the patients, type of glaucoma, side of treatment, quadrants treated are given in Table 1 . Effectiveness of treatment was seen in 85.7% cases. We found insignificant association of effectiveness with gender (p = 0.199), age groups (p = 0.096), type (p = 0.656) and procedure (p = 0.231) as shown in Table- 2.
Mean pre-op IOP, after 1 week, 1 month and 3 months for unilateral and bilateral cases is shown in Table- 3. Acetazolamide was not given to 35(35.7%) cases while stopped for 53 (54.1%) cases and 10(10.2%) cases continued with acetazolamide.
Mean post-operative IOP at each time point was significantly lower than pre op IOP for unilateral (right and left eye) and bilateral (right and left eye) cases as shown in Figure 1 (a), Figure 1 (b), Figure 2 (a) and Figure 2 (b). Significant mean difference was found for pre-op IOP with IOP after 3 months for unilateral right eye (p = 0.000), unilateral left eye (p = 0.00), Bilateral right eye (p = 0.000) and Bilateral left eye ( p =0.000) as presented in Table-4. Our complications which were generally tolerated well were conjunctival hemorrhage because of the tip of the probe, which resolved later. The most significant but rare side effect seen was severe surface epithelial erosion all over cornea and it took 3-6 weeks to come back to normal with Autologus serum. In one patient, permanent central scar was formed because of infection. Four to five patients did not respond to treatment even after repeating the procedure after 3 months. We could not explain this phenomenon. Pak J Ophthalmol delivers continuous, high intensity energy, MP3 delivers repetitive short pulse laser energy series followed by rest period 8, 15, [16] [17] [18] . Complications related to cyclodestruction procedure includes vision loss, pupillary distortion, corneal edema, cystoid macula, hypotony, and edema 19, 20 .
Micro pulse MP3 cyclophotocoagulation showed effectiveness for 85.7% of the cases in our study which is nearly same as reported by Kareen Zaroor (81.7%) 21 . Yelenskiy A reported 71% effectivness. 19 Success rate varies from 40% to 80% in different studies [22] [23] [24] .
The advent of micro-pulsed trans-scleral diode laser has revolutionized diode laser as well as other laser types, even CO2 laser. Concept of micro-pulsing allows maximum effectiveness by generating significant amounts of energies to reach target tissues and allowing time for heat to diffuse instead of building up, to reduce the risk of unwanted side effects and to make this laser safe and predictable enough to use in seeing eyes 1 . The procedure is wellknown for its ease, non-invasiveness and well toleration. Bleeding and postoperative infection risks are eliminated by trans-scleral application. At every level of the glaucoma spectrum, MP3 is shown as safe and effective procedure for affected eyes 1 .
Excellent safety profile is documented with this treatment. One of the recent studies also reported very good results of the procedure with no complications (i.e. phthisis bulbi, hypotony and macular edema). 6 In our study, we found significant mean difference for pre-op IOP with IOP after 3 months for right eye (p = 0.000) and left eye (p = 0.00). Emanuel et al. showed higher reduction of IOP 24 , this has been attributed both to the possibility of increased uveoscleral outflow, as well as decreased aqueous production 22 .
Emanuel et al also reported reduction in the need of topical eye drops 21 . Other studies also reported lesser need of number of eye drops 10 . However, it is noteworthy that in 54% of the patients in our study we were able to withdraw acetazolamide tablets, a treatment that was not used in other studies 1, 16, 24 . This could explain the reason why the number of hypotensive drops did not decrease as drastically as reported in other studies 24 .
The limitation of our study is the short-term follow up but we are continuing our study for long term follow-up. Previously, cyclodestructive procedures such as cyclocryotherapy and CPC were reserved for poorly controlled glaucoma, limited visual prognosis and mainly retained for end stage glaucoma, because of associated complication with cyclodestructive procedures that include vision loss, corneal edema, pupillary distortion, cystoid macula edema, and hypotony 19 . We did not notice any significant complications following MP-TSCPC in our study. Tan et al found MP-TSCPC comparable to conventional TSCPC with potentially lower rate of complication 23 .
CONCLUSION
This new method of micropulse delivery may be of help in patients who cannot take medications or want to delay incisional surgery. Micro pulse MP3 can thus be a viable option in patients with prior failed filtering surgery, given the fact that repetition of incisional glaucoma procedures can be technically demanding and fraught with complications, not to mention the lower success rates of glaucoma reoperations. Micro pulse MP3 provides promising results with high level of effectiveness and with great potential advantages to be considered as a safe alternative procedure.
